InSysBio to publish the new article on identifiability analysis in PLOS Computational Biology

NEWS
Publication
January 14, 2021

January 11, 2021

[Moscow – 11.01.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has published its recent scientific research on identifiability in PLOS Computational Biology. The article, named “Confidence intervals by constrained optimization—An algorithm and software package for practical identifiability analysis in systems biology” was developed by the researchers Ivan Borisov and Evgeny Metelkin.

The present article contributes an algorithm Confidence Intervals by Constraint Optimization (CICO) based on profile likelihood, aimed to speed-up confidence intervals estimation and reduce computational cost. The numerical implementation of the algorithm includes settings to control the accuracy of confidence intervals estimates. The algorithm was tested on a number of Systems Biology models, including Taxol treatment model and STAT5 Dimerization model.

Evgeny Metelkin, Head of product development, comments on the study, “Ivan Borisov and I have developed the method which demonstrates better performance and reliability in comparison with previously applied. In the absence of identifiability analysis, one can never be certain how reliable parameters estimation and how accurate the model predictions are. However, practical usage of the analysis has not become a standard routine yet due to a number of challenges. The most critical one is that all the methods are computationally demanding. Our approach is less time-consuming and can be run for large-scale QSP models”.

The code and the examples are freely available on the repository

More InSysBio’s publications are available here

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

May 2025
MoTuWeThFrSaSu
   
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1. 15 May 2025 15:07 15th InSysBio’s Annual Internal Scientific Meeting InSysBio held its 15th Annual Internal Scientific Meeting. The Meeting traditionally passed in warm, friendly atmosphere and the discussion was efficient and uniting.
16
17
18
19
20
21
1. 21 May 2025 16:55 InSysBio to take part in PAGE 2025 InSysBio announces its participation in the Thirty-third PAGE Meeting which is to be held from 4-6 June, 2025, at the Thessaloniki Concert Hall in Thessaloniki, Greece. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #10 in the upper foyer and 2 posters in frames of the Meeting
22
23
24
25
26
27
28
29
30
1. 30 May 2025 15:23 InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics The new article “Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data” has been recently published in CPT: Clinical Pharmacology & Therapeutics
31
 
Upcoming Events
04.06
InSysBio to take part in PAGE 2025
Tags
Latest News
30.05
InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics
15.05
15th InSysBio’s Annual Internal Scientific Meeting
09.04
InSysBio to release a new version of LikelihoodProfiler.jl
31.03
InSysBio to launch Immune Response Template version 3.7.0 for QSP modeling
19.03
InSysBio announces its collaboration with discoveric bio alpha